

Cite this as: Haohua LU, Yu SHI, Kelie CHEN, Zhi CHEN, Haihong ZHU, Yuequn NIU, Dajing XIA, Yihua WU. Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis[J]. Journal of Zhejiang University Science B, 2021, 22(10): 876-884.
<http://doi.org/10.1631/jzus.B2100151>

Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis

Key words: COVID-19, cancer, antitumor regimens, pooled analysis

Research Summary


This study provided a comprehensive analysis of anticancer regimens and their impacts on cancer patients with COVID-19

We focused on two major outcomes:

- **All-cause death**
- **Severe events (death, admission to an intensive care unit (ICU), and utilization of mechanical ventilation)**


Innovation points

- **Attention** on the role of anticancer regimens in the pandemic of COVID-19.
- **Pooled analysis** of the previous studies with available individual data.



Surgery

Chemotherapy



Immunotherapy




Hormonal therapy

Radiotherapy


Targeted therapy

Main results

A




B



- **Effects of antitumor regimens** became insignificant after adjustment
- **Effects of crucial clinical characteristics** (advancing age and comorbidities) should deserve more attention

Main results



- **Immunotherapy** affects COVID-19 patients with solid tumors
- **Chemotherapy** affects COVID-19 patients with haematological malignancies